Bayer CEO Marijn Dekkers thinks Pfizer ($PFE) is most likely to spin off its animal health unit. But the German company made a preliminary offer anyway, Dow Jones reports, citing the Financial Times Deutschland.
Germany's Stada wants to expand in Russia. But attempts to buy Russian drugmakers have so far failed--despite months of effort--leaving the company with a big debt burden and stagnant home market, Reuters reports.
Pfizer ($PFE) CEO Ian Read (photo) told the Financial Times that he hopes to divest the company's animal health and nutrition units by June 13.
Fresh off a disappointing decision to jerk its marketing application for Replagal, Shire bounced right back with its announcement that it has scooped up the Bay Area biotech FerroKin BioSciences in a $325 million deal. Shire is paying $100 million upfront for FerroKin, with the rest offered in potential milestones.
As far as most biotech investors are concerned, the most exciting work being done in the hepatitis C field involves next-gen treatments that can potentially quell the virus without the need for the troublesome interferon in the combo.
The FDA has officially denied AstraZeneca's petition to hold off generic versions of its antipsychotic drug Seroquel.
Pharma M&A activity is heating up, particularly among medium-sized companies, and shows signs of accelerating further, MarketWatch reports.
Sanofi ($SNY) CEO Chris Viehbacher (photo) managed to parlay one personal appearance into a half-dozen different headlines. Development strategies? Check. M&A interest? Check. Job creation?...
Bidding to up its game in the antibody business, the U.K.'s Abcam has snapped up California-based Epitomics for $155 million.
GlaxoSmithKline ($GSK) is steaming ahead in China. CEO Andrew Witty (photo) tells Bloomberg he plans to add "a few hundred" sales folks to back up products his company is introducing there. That's on top of 700 hires in 2011. And, Witty said, he'd like to augment his Chinese operations with some M&A, too.